Background: Fibroid is the commonest benign tumor of the uterus and also commonest benign solid tumor in females. Fibroids are found to be 2-3 times more prevalent in obese women, specially the one’s with central obesity and in those with BMI > or = 35. Epidemiologic data also shows pregnancy is associated with reduced risk of fibroids. So, the present study will be a cross-sectional study which will be undertaken to know the association of uterine leiomyoma with BMI and parity in the women of coastal Karnataka.Methods: An analytical cross-sectional study was performed among the 100 patients attending OPD at the department of obstetrics and gynecology, Karwar institute of medical sciences from June 2018 to August 2018. Women suspected to have fibroid based on their symptoms were made to undergo ultrasonography. Comparison was made between the parity, body mass index of the patient and the size of the uterine fibroid visualized.Results: Out of 100 women studied 63 were nulliparous and 37 women were multiparous. Incidence of fibroid is inversely proportional to parity. When BMI < 18 only 6 women had fibroid, when BMI > 25, 57 women had fibroids and between 18-25 group 37 women were diagnosed with fibroid.Conclusions: The fibroid showed directly proportional association with BMI. Greater the BMI, more was the risk of fibroids. The fibroid showed inversely proportional association with parity. Greater the parity of the women lesser was her chances of being at risk of having fibroid.

OBJECTIVE: Determination of adverse pregnancy out come and complications in teenage pregnancy. MATERIAL AND METHODS: Total 258 cases were studied from Hospital Records in the OBG dept of Navodaya Medical College, Raichur, which were enrolled during the study period. Out of cases, 43 were teenagers and others 215 were non-teenagers. RESULTS: Out of 43 cases, 29 (67.5%) were primigravida, 10(23.25%) were Gravida-2, 3 (7%) were Gravida-3 and 1(2.25) were Gravida-4. All of these cases had complications like 12 (28%) Low birth weight babies, 10 (24%) had PIH, 6(14%) had CPD 5(12%) had IUD, 4(10%) were Anemic, Fetal distress cases were 3 (8%) and 1 (2.5%) was abortion and anencephaly each. All the 43 cases had worst outcome of pregnancy. 6(14%) delivered prematurely, 5 (11.5%) had macerated stillbirth, 19(44%) of cases had undergone Caesarean-section for which indications were CPD, fetal distress, breech presentation, PROM and previous LSCS history. Incidence of C Section in this study was 44% which is higher as compared to other studies .Reproductive losses in the form of abortions and stillbirth. Perinatal Mortality was 23.5%. CONCLUSION: In this study outcome of pregnancy was adverse in most of the teenage pregnancies. It is pointer towards a need to discourage teenage pregnancy and consequently reduce wastage of deliveries, low birth weight through an intensive campaign for proper marriage age of girls.

Introduction: Pregnancy-induced hypertension (PIH) is a highly prevalent pregnancy complication with adverse effects on maternal and infant health. Birth weight is a key predictor of Newborn outcome and indicator of health in Newborn. The objective of our study is to find the association between severity of PIH on birth weight of new born. Methods: A prospective study involving 100 pregnant women with PIH, visiting out patient department of OBG, at Karwar institute of medical sciences hospital, was conducted from July 2019 to January 2020. Parameters such as blood pressure, serum uric acid, grade of PIH, birth weight of Newborn post delivery were noted. Data was analyzed by chi-square test. Result: This study observed the reduction in the weight of new born with increase in severity of PIH. Conclusion:Present study shows that, PIH adversely affects the weight of Newborn. With increase in severity of PIH, birth weight of new born decreases.

Prospective hospital based comparative study conducted over a period of one and half years. Study population includes 100 pregnant women in third trimester. Out of which 50 were normal pregnant women and 50 were HDP women. After admission history, physical examinations done and directed for laboratory studies like platelet count using automated blood cell counter. OBSERVATION: In study group out of 50 women 24 (48%) were between 21-25 yrs of age, showing more incidence in primigravida 35 (70%). The 29 (58%) had gestational hypertension and (14)28 % had mild to moderate thrombocytopenia with mean platelet count of 1.76 lakhs/cumm. In control group (7)14% had gestational thrombocytopenia with mean platelet count of 2.07 lakhs/cumm. Overall 20% hypertensive pregnant had thrombocytopenia. The incidence of the complications in the study group was 56%. The mean platelet count in complications secondary to HDP was within normal range. CONCLUSION: The incidence of Gestational thrombocytopenia is 14%. It doesn't have any effect on pregnancy. Perinatal outcome is basically favourable. Thrombocytopenia in HDP is of mild to moderate variety about 28% and rarely drops below severe level. HDP are affecting outcome of pregnancy in the form of complications without causing variation in the platelet count. Complications occuring are attributable to HDP but not due to thrombocytopenia.

BACKGROUND Dysfunctional Uterine Bleeding is defined as abnormal uterine bleeding in the absence of organic disease. Regarding the medical management of DUB, several drugs have been used, however there is lack of studies suggesting the most appropriate drug. The objective of the study was to compare the two drugs, Norethisterone a progesterone derivative and Ormeloxifene, a selective oestrogen receptor modulator in terms of effectiveness and safety. MATERIALS AND METHODS Women attending Gynaec OPD s with DUB were chosen for the study. Sample size was hundred which was divided in 2 groups. Ormeloxifene 60mg twice weekly for 12 weeks followed by once a week for another 12 weeks was given in group A. Group B women received norethisterone 5mg twice a day from day 5 to day 26 of a cycle for 6 months. Primary outcome parameters noted were reduction in menstrual blood loss as measured by fall in PBAC (Pictorial Blood Loss Assessment Chart) score, increase in haemoglobin, and decrease in endometrial thickness at the end of the study. RESULTS Ormeloxifene showed a better reduction in mean PBAC score (225 to 75) compared to norethisterone (234 to 110) at 6 months (p<0.01). Similarly, group A (Ormeloxifene) showed statistically significant increase in haemoglobin concentration (7.2 g% to 10.5 g% vs. 7.6 g% to 9.9 g%, (p<0.05) and reduction in endometrial thickness from 11.8mm to 6.6mm vs. 11.2mm to 8.1mm, p<0.05, respectively, in comparison to Group B (Norethisterone). None of the cases reported any major side effects in the study. CONCLUSION Ormeloxifene is superior to norethisterone in reducing menstrual blood loss, as well as improving perimenopausal symptoms and thus in the treatment of perimenopausal DUB.